No Data
No Data
Fractyl Health to Present New Preclinical Data From Its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
Fractyl Health to Participate in the Upcoming December Conferences
Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript Summary
BofA Securities Maintains Fractyl Health(GUTS.US) With Buy Rating
Fractyl Health's Strategic Advancements and Promising Data Drive Buy Rating
Morgan Stanley Maintains Fractyl Health(GUTS.US) With Buy Rating, Maintains Target Price $18